Study type

Study type

Non-interventional study

Scope of the study

Assessment of risk minimisation measure implementation or effectiveness
Drug utilisation
Effectiveness study (incl. comparative)
Non-interventional study

Non-interventional study design

Other

Non-interventional study design, other

Long-term observational registry
Study drug and medical condition

Name of medicine

TRANSLARNA

Medical condition to be studied

Duchenne muscular dystrophy gene carrier

Additional medical condition(s)

Nonsense mutation in the dystrophin gene
Population studied

Age groups

Children (2 to < 12 years)
Adolescents (12 to < 18 years)
Adults (18 to < 46 years)
Adults (46 to < 65 years)
Adults (65 to < 75 years)
Adults (75 to < 85 years)
Adults (85 years and over)

Estimated number of subjects

360
Study design details

Main study objective

The study is designed to evaluate the long-term safety and effectiveness, and utilization pattern of Translarna in real-world routine clinical practice.

Outcomes

The objectives of the study are: • Obtain additional information on all safety concerns being tracked in the Risk • Management Plan and the long-term safety profile of Translarna • Obtain additional information on the long-term effectiveness of Translarna. • Monitor the utilization pattern of Translarna in usual care.

Data analysis plan

For any given safety event, the unadjusted incidence rate and exposure-adjusted event rate will be calculated, along with exact binomial confidence intervals. Further details of the analyses will be included in the SAP. Specific analyses on safety concerns with ataluren treatment will be performed when data available. The effectiveness of treatment with Translarna will be evaluated in the context of data were available: 6MWT, timed function tests, NSAA, PUL, cardiac and pulmonary functions. Data from these assessments will be summarized by visit. Changes in the relevant variable from baseline to each post-baseline visit will be summarized descriptively. Changes from baseline to each post-baseline visit will be analysed using paired t-tests. Results will be presented combined and stratified as appropriate. Subgroup analyses will be performed.
Documents